Sionna Therapeutics Aktie
Marktkapitalisierung
1,66 Mrd. $
1,66 Mrd. $
Streubesitz
0%
KGV
-21,88
Index-Zuordnung
-
Sionna Therapeutics, Inc. Common Stock Unternehmensprofil
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Vorstand
Herr Michael Cloonan M.B.A.
Präsident, CEO & Direktor
Ms. Elena H. Ridloff C.F.A.
Finanzvorstand
Frau Caroline Stark Beer M.B.A.
Geschäftsführender Direktor
Dr. Greg Hurlbut Ph.D.
Mitbegründer & Senior VP der Entdeckungsforschung
Dr. Mark Munson Ph.D.
Mitbegründer & Senior VP der Medizinischen Chemie
Frau Meghan Bagshaw
Vizepräsident für Programme, Portfolio & Betrieb
Herr Andy Chu
Vizepräsident für Information & Technik
Frau Jennifer Fitzpatrick J.D.
Leiter der Rechtsabteilung
Frau Vanya Sagar
Verantwortlicher für das Personalwesen
Dr. Charlotte McKee M.D.
Leitender medizinischer Offizier
Aktionärsstruktur
Termine
Stammdaten
| Nennwert/Aktie | - |
| Land | USA |
| Währung | USD |
| Branche | Biotechnologie |
| Aktientyp | - |
| Sektor | Gesundheit |
| Gattung | - |
Quelle: Leeway